---
title: "Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294090677.md"
description: "Norstella, a prominent worldwide supplier of AI-driven pharmaceutical intelligence solutions, has introduced the Pipeline-to-Patient Productivity Index. This annual benchmark assesses research and development productivity, market access, and commercial return within the top 25 global biopharmaceutical companies. This index serves as a comprehensive tool for evaluating industry performance."
datetime: "2026-07-28T15:42:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294090677.md)
  - [en](https://longbridge.com/en/news/294090677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294090677.md)
generator: "portal-rs"
---

# Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle

Norstella, a prominent worldwide supplier of AI-driven pharmaceutical intelligence solutions, has introduced the Pipeline-to-Patient Productivity Index. This annual benchmark assesses research and development productivity, market access, and commercial return within the top 25 global biopharmaceutical companies. This index serves as a comprehensive tool for evaluating industry performance.

## Related News & Research

- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [Bio-Works wins SEK 2.8 million order from new US mRNA medicine developer](https://longbridge.com/en/news/296870494.md)
- [Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update | NIKA Stock News](https://longbridge.com/en/news/296928702.md)
- [St Joseph subsidiary Fastbase AI prepares beta launch of global business search platform](https://longbridge.com/en/news/296792561.md)
- [Filament Health ships psilocybin candidate PEX010 for University of Washington Phase 2a cancer anxiety, depression trial](https://longbridge.com/en/news/296906129.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**